# Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy

> **NCT01220609** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Recurrent Uterine Corpus Sarcoma
- Uterine Corpus Leiomyosarcoma

## Interventions

- **DRUG:** Ixabepilone
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01220609
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-07
- **Final completion:** 2016-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01220609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01220609, "Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01220609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*